Global cord blood corporation reports financial results for the fourth quarter and full year of fiscal 2022

Added 16,423 new subscribers in 4qfy22 4qfy22 revenues down 1.7% yoy to rmb297.2 million ($46.9 million) 4qfy22 gross profit down 0.5% yoy to rmb255.2 million ($40.3 million) 4qfy22 operating income down 4.1% yoy to rmb142.1 million ($22.4 million) 4qfy22 non-gaap operating income down 4.1% yoy to rmb153.9 million ($24.3 million) hong kong , july 5, 2022 /prnewswire/ -- global cord blood corporation (nyse: co) ("gcbc" or the "company"), china's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for the fourth quarter and full year of fiscal 2022, ended march 31, 2022. fourth quarter fiscal 2022 highlights new subscribers decreased by 15.2% year-over-year ("yoy") to 16,423 due to anti-pandemic measures, as well as fewer newborns in our operating regions, while accumulated subscriber base expanded to 970,375[1].
CO Ratings Summary
CO Quant Ranking